Ticker: RCKT

Rocket Pharmaceuticals (NASDAQ: RCKT) sees a 57% premarket drop following a patient death linked to their clinical trial. The FDA has imposed a hold as Rocket reassesses its strategy and financials. Traders face risks, balancing potential recovery against safety concerns.